24 papers
Obstetrics and gynecology encompasses the vital care of women's health throughout life, from reproductive wellness and pregnancy to menopause and beyond. This dynamic field explores the complex biological processes of childbirth, the prevention of diseases affecting female reproductive organs, and the latest advancements in maternal safety. It is a discipline deeply rooted in both immediate clinical impact and long-term public health strategies.
On Gist.Science, we continuously monitor medRxiv for the newest preprints in this category, ensuring you have instant access to cutting-edge research before formal publication. Our team processes every new submission to provide both detailed technical summaries and clear, plain-language explanations, making these complex studies understandable for everyone from specialists to curious readers.
Below are the latest papers in obstetrics and gynecology, offering fresh insights into the future of women's healthcare.
This study demonstrates that supervised machine learning models trained on linked mother-infant electronic health records can accurately and generalizably estimate gestational age at delivery across different health systems, providing a robust framework to support large-scale maternal and neonatal health research.
Through a three-phase consensus process involving systematic reviews, a Delphi survey, and stakeholder meetings, this study identified 62 priority maternal and child outcomes to be included in a decision aid that supports informed choices between planned vaginal and caesarean births.
This manuscript regarding longitudinal antenatal care quality and postpartum health in Ethiopia, India, Kenya, and South Africa has been withdrawn by the authors to finalize their work and should not be cited.
The INSIGHT study is a large, prospective UK cohort that established a deeply phenotyped dataset of 2,272 pregnant women to identify early biomarkers for spontaneous preterm birth by integrating multi-omic analyses of the innate immune response, vaginal microbiome, and host biology, ultimately demonstrating that maternal plasma cfRNA and combined biological markers can predict risk months before clinical presentation.
This retrospective study of 58 obstetric ICU admissions at a tertiary urban center reveals that 81% of patients were non-Hispanic Black and 91% were publicly insured, highlighting local disparities that align with national trends of elevated severe maternal morbidity and mortality among Black women and those with Medicaid coverage.
This study protocol outlines a double-blind, randomized controlled trial in Lagos, Nigeria, designed to evaluate whether daily oral N-acetylcysteine (NAC) can delay the progression of early-onset preeclampsia to severe disease compared to a placebo, potentially offering a safe and affordable intervention for resource-constrained settings.
This population-based study of over 41 million U.S. births from 2014 to 2024 reveals that racial and ethnic disparities in cesarean delivery rates persist independently of insurance status, with non-Hispanic Black women facing the highest risks across all coverage types and the most significant absolute disparities observed among the uninsured.
This two-sample Mendelian randomization study with maternal-fetal effect decomposition provides robust evidence that genetic liability to endometriosis causally increases the risk of placenta praevia through maternal pathways, while suggesting that previously observed associations with other adverse pregnancy outcomes are likely driven by confounding factors rather than direct causality.
This mixed-method study of 300 undergraduates at Osun State University reveals that students possess low knowledge and predominantly negative attitudes toward male infertility, which are significantly influenced by academic level, faculty, and formal education, highlighting the urgent need for gender-inclusive health education to address cultural misconceptions.
In a randomized, double-blind, placebo-controlled trial involving 40 women, oral L-ergothioneine supplementation (120 mg/day) significantly and progressively reduced primary dysmenorrhea pain and associated symptoms over three menstrual cycles without adverse events, suggesting a cytoprotective mechanism independent of classical inflammatory pathways.